Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis

Company Overview

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) is a clinical-stage biotechnology company dedicated to developing innovative therapies for serious eye diseases. The company’s research efforts focus on modulating immune and neurological pathways in the eye to address conditions that currently have limited treatment options. Kiora’s approach combines small-molecule immunomodulators with advanced gene-based and optogenetic technologies to preserve and restore vision.

The company’s lead product candidate, KIO-100 (PP-001), is an intravitreal formulation designed to inhibit key inflammatory pathways implicated in non-infectious uveitis and other autoimmune ocular disorders. KIO-100 has completed initial Phase 1 safety studies, demonstrating tolerability and preliminary signs of localized immune modulation without systemic exposure.

Kiora’s second program, KIO-301, leverages optogenetic therapy to introduce light-sensitive proteins into retinal cells, offering a potential treatment for retinitis pigmentosa and other degenerative retinal diseases. This platform aims to restore visual function by converting surviving retinal neurons into artificial photoreceptors, and it is currently advancing through preclinical development and manufacturing scale-up.

Headquartered in the United States, Kiora collaborates with academic institutions and contract research organizations to support its clinical and preclinical programs. The company’s leadership team comprises experienced executives and scientists drawn from both ophthalmology and biotechnology sectors, all working toward delivering novel treatments for patients with unmet visual needs.

Key Stats

• Today's Range: $2.70 to $2.95
• 50-Day Range: $2.36 to $2.93
• 52-Week Range: $2.25 to $4.18
• Volume: 120,456 shs
• Average Volume: 36,271 shs
• Market Capitalization: $9.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Hold

Kiora Pharmaceuticals Stock Analysis - MarketRank™

Kiora Pharmaceuticals scored higher than 53% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Kiora Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Kiora Pharmaceuticals has a consensus price target of $10.00, representing about 266.3% upside from its current price of $2.73.

Amount of Analyst Coverage

Kiora Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kiora Pharmaceuticals are expected to decrease in the coming year, from $1.28 to ($2.76) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kiora Pharmaceuticals is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kiora Pharmaceuticals is -0.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kiora Pharmaceuticals has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.22% of the float of Kiora Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Kiora Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kiora Pharmaceuticals has recently decreased by 83.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kiora Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Kiora Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.22% of the float of Kiora Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Kiora Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kiora Pharmaceuticals has recently decreased by 83.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

2 people have added Kiora Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kiora Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.05% of the stock of Kiora Pharmaceuticals is held by insiders.

Percentage Held by Institutions

76.97% of the stock of Kiora Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KPRX Stock Analysis - Frequently Asked Questions

How have KPRX shares performed this year?

Kiora Pharmaceuticals' stock was trading at $3.30 at the beginning of 2025. Since then, KPRX shares have decreased by 17.3% and is now trading at $2.73.

How were Kiora Pharmaceuticals' earnings last quarter?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) issued its quarterly earnings data on Friday, August, 8th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.04. The company earned $0.75 million during the quarter, compared to the consensus estimate of $0.75 million.

When did Kiora Pharmaceuticals' stock split?

Kiora Pharmaceuticals shares reverse split on Tuesday, June 11th 2024.The 1-9 reverse split was announced on Tuesday, June 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split.

How do I buy shares of Kiora Pharmaceuticals?

Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kiora Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kiora Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 8/08/2025
• Today: 10/08/2025
• Next Earnings (Estimated): 11/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KPRX
• CIK: 1372514
• Web: eyegatepharma.com
• Phone: (781) 788-9043
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Kiora Pharmaceuticals: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +266.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 2.13
• P/E Growth: N/A
• Net Income: $3.60 million
• Net Margins: N/A
• Pretax Margin: -49,315.00%
• Return on Equity: -47.17%
• Return on Assets: -34.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.76
• Quick Ratio: 7.76

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $1.24 per share
• Price / Cash Flow: 2.20
• Book Value: $8.58 per share
• Price / Book: 0.32

Miscellaneous

• Outstanding Shares: 3,434,000
• Free Float: 3,432,000
• Market Cap: $9.37 million
• Optionable: Not Optionable
• Beta: -0.67